CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total costs of diabetes care The ADA Scientific ...
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in ...
Fractyl Health to present preclinical data on gene therapy for obesity and type 2 diabetes at ADA’s Scientific Sessions. Fractyl Health, Inc. has announced it will present new preclinical data from ...
CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total costs of diabetes care CHICAGO--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results